Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Original Article
Short and long-term safety and durability of PEG-J tube in jejunal levodopa infusion in patients with Parkinson’s disease
Aims: To investigate PEG-J related adverse events and tube durability in patients with Parkinson’s disease who underwent PEG-J procedure for jejunal drug infusion.
Methods: PEG-J implanted patients, who were planned jejunal levodopa infusion, were included in the study. The demographic characteristics of the patients, tube durability, tube replacement, reason for tube replacement, number of procedures, and adverse events related to procedures were retrospectively analyzed.
Results: Thirty-four patients with a mean age of 65.7±9.8 years included in the study. The mean total PEG-J follow-up period of the patients was 33.6±21.1 months. Functions of PEG-J tubes were preserved in 82.5% at 6 months, 78.4% at 12 months, and 65.2% at 18 months. Twenty-one (% 61,8) patients required at least one PEG-J replacement. Of the PEG-J replacements, 90.4% were due to device-related adverse events. A total of 29 procedure or stoma related adverse events occurred in 21 (61.8%) patients, and a total of 28 PEG-J tube related adverse events occurred in 19 (55.9%) patients. A total of six (17.5%) early procedure-related adverse events (acute abdomen and peritonitis, prolonged bleeding, stoma leakage, stoma infection) were observed, all occurred in first 7 days. Twenty-three (67.6%) stoma-related late adverse events (stoma leakage, stoma infection, abscess) were observed. Two patients who developed peritonitis were successfully treated with conservative treatments.
Conclusion: PEG-J used for drug application is a safe method and can be used for a long time without the need for frequent replacement. Most of adverse events can be managed with conservative treatments.

1. Arvanitakis M, Gkolfakis P, Despott EJ, et al. Endoscopicmanagement of enteral tubes in adult patients - part 1: definitionsand indications. European Society of Gastrointestinal Endoscopy(ESGE) Guideline. Endoscopy. 2021;53(1):81-92.
2. Deliwala SS, Chandan S, Kumar A, et al. Direct percutaneousendoscopic jejunostomy (DPEJ) and percutaneous endoscopicgastrostomy with jejunal extension (PEG-J) technical success andoutcomes: Systematic review and meta-analysis. Endosc Int Open.2022;10(4): E488-E520. doi:10.1055/a-1774-4736
3. Kamel WA, Al-Hashel JY. LCIG in treatment of non-motor symptoms in advanced Parkinson’s disease: reviewof literature. Brain Behav. 2020;10(9): e01757. doi:10.1002/brb3.1757
4. Blaise AS, Baille G, Carrière N, et al. Safety and effectivenessof levodopa-carbidopa intestinal gel for advanced Parkinson’sdisease: a large single-center study. Rev Neurol (Paris).2020;176(4):268-276.
5. Antonini A, Odin P, Pahwa R, et al. The long-term impact oflevodopa/carbidopa intestinal gel on ‘off ’-time in patients withadvanced Parkinson’s disease: a systematic review. Adv Ther.2021;38(6):2854-2890.
6. Othman AA, Chatamra K, Mohamed ME, et al. Jejunal infusionof levodopa-carbidopa intestinal gel versus oral administration oflevodopa-carbidopa tablets in Japanese subjects with advancedParkinson’s disease: pharmacokinetics and pilot efficacy andsafety. Clin Pharmacokinet. 2015;54(9):975-984.
7. Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel fortreatment of advanced Parkinson’s disease. Curr Med Res Opin.2011;27(5):907-919.
8. Cococcia S, Rovedatti L, Lenti MV, Pozzi L, De Grazia F, DiSabatino A. Safety and durability of PEG-J: a single-centreexperience. Scand J Gastroenterol. 2020;55(11):1377-1380.
9. Udd M, Lyytinen J, Eerola-Rautio J, et al. Problems relatedto levodopa-carbidopa intestinal gel treatment in advancedParkinson’s disease. Brain Behav. 2017;7(7): e00737. doi:10.1002/brb3.737
10. Viljaharju V, Mertsalmi T, Pauls KAM, et al. Single-center studyof 103 consecutive Parkinson’s disease patients with levodopa-carbidopa intestinal gel. Mov Disord Clin Pract. 2021;9(1):60-68.
11. Standaert DG, Rodriguez RL, Slevin JT, et al. Effect of levodopa-carbidopa intestinal gel on non-motor symptoms in patientswith advanced Parkinson’s disease. Mov Disord Clin Pract.2017;4(6):829-837.
12. Lopiano L, Modugno N, Marano P, et al. Motor and non-motoroutcomes in patients with advanced Parkinson’s disease treatedwith levodopa/carbidopa intestinal gel: final results of theGREENFIELD observational study. J Neurol. 2019;266(9):2164-2176.
13. Epstein M, Johnson DA, Hawes R, et al. Long-term PEG-J tubesafety in patients with advanced Parkinson’s disease. Clin TranslGastroenterol. 2016;7(3): e159. doi:10.1038/ctg.2016.19
14. Cheron J, Deviere J, Supiot F, et al. The use of enteral access forcontinuous delivery of levodopa-carbidopa in patients withadvanced Parkinson’s disease. United European Gastroenterol J.2017;5(1):60-68.
15. Ishibashi Y, Shimo Y, Yube Y, et al. Technique and outcome ofpercutaneous endoscopic transgastric jejunostomy for continuousinfusion of levodopa-carbidopa intestinal gel for treatment ofParkinson’s disease. Scand J Gastroenterol. 2019;54(6):787-792.
16. Yamashita K, Yube Y, Yamazaki Y, et al. The impact of tubereplacement timing during LCIG therapy on PEG-J associatedadverse events: a retrospective multicenter observationalstudy. BMC Neurol. 2021;21(1):242.
17. Simoni S, Nigro P, Filidei M, et al. PEG-J replacement forduodenal levodopa infusion in Parkinson’s disease patients: aretrospective study. BMC Neurol. 2022;22(1):25.
18. Rus T, Premzl M, Kriznar NZ, et al. Adverse effects of levodopa/carbidopa intrajejunal gel treatment: a single-center long-termfollow-up study. Acta Neurol Scand. 2022;146(5):537-544.
19. Zopf Y, Konturek P, Nuernberger A, et al. Local infection afterplacement of percutaneous endoscopic gastrostomy tubes: aprospective study evaluating risk factors. Can J Gastroenterol.2008;22(12):987-991.
20. Yamanishi Y, Choudhury ME, Yoshida A, et al. Impact ofintestinal bacteria on levodopa pharmacokinetics in LCIGtherapy. Mov Disord Clin Pract. 2022;9(3):362-368.
21. de Vries T, de Ruiter A, Westendorp A, van Zeijl J. Microorganismsand complaints in outpatients with a percutaneous endoscopicgastrostomy catheter. Am J Infect Control. 2015;43(8):802-804.
22. Wirth R, Bauer J, Sieber C. Necrotizing Candida infectionafter percutaneous endoscopic gastrostomy: a fatal and rarecomplication. JPEN J Parenter Enteral Nutr. 2008;32(3):285-287.
Volume 4, Issue 5, 2023
Page : 389-394